Grand Brilliance Group Holdings (HKSE:08372) Research & Development: HK$0.0 Mil (TTM As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HKSE:08372 Grand Brilliance Group Holdings Ltd HKSE:08372
66 GF Score
Price HK$0.13
GF Value HK$0.12
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Grand Brilliance Group Holdings Research & Development?

Grand Brilliance Group Holdings HKSE:08372 66 Research & Development is HK$0.0 Mil as of Mar. 2026. GuruFocus rates HKSE:08372 with a GF Score™ of 66/100 and a GF Value™ of HK$0.12 (Fairly Valued). The stock has 5 warning signs investors should review.

Research & Development is the aggregate amount of research and development expenses during the year. Grand Brilliance Group Holdings's Research & Development for the six months ended in Mar. 2026 was HK$0.0 Mil. Its Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 was HK$0.0 Mil.

Grand Brilliance Group Holdings  (HKSE:08372) Research & Development Explanation

If competitive advantage is created by a patent or tech advantage, at some point it will disappear.

High R&D usually dictates high SG&A which threatens the competitive advantage.

Grand Brilliance Group Holdings Research & Development Related Terms

Grand Brilliance Group Holdings Research & Development Historical Data

* Premium members only.

The historical data trend for Grand Brilliance Group Holdings's Research & Development can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Grand Brilliance Group Holdings Research & Development Chart

Grand Brilliance Group Holdings Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Research & Development
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Grand Brilliance Group Holdings Semi-Annual Data
Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25 Mar26
Research & Development Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
HKSE:08372
66GF Score
Grand Brilliance Group Holdings Ltd HKSE:08372
Research & Development is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Grand Brilliance Group Holdings Research & Development Calculation

This is the expense the company spent on research and development.

Research & Development for the trailing twelve months (TTM) ended in Mar. 2026 adds up the semi-annually data reported by the company within the most recent 12 months, which was HK$0.0 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Research & Development →
What does a Research & Development of HK$0.0 Mil mean?
Grand Brilliance Group Holdings (HKSE:08372) has a Research & Development of HK$0.0 Mil as of Mar. 2026. Research and development expense is the total cost for research and development activities. View historical data on Grand Brilliance Group Holdings and its competitors.
Is Grand Brilliance Group Holdings' Research & Development too high?
Grand Brilliance Group Holdings' current Research & Development is HK$0.0 Mil. Overall, Grand Brilliance Group Holdings has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Grand Brilliance Group Holdings' Research & Development compare to MCK and COR?
Grand Brilliance Group Holdings' Research & Development of HK$0.0 Mil can be compared against companies in the Medical Distribution industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Research & Development for a Medical Distribution company?
A good Research & Development depends on the Medical Distribution industry context. However, Research & Development should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Research & Development mean?
A high Research & Development can signal that a stock is expensive relative to its fundamentals. Research and development expense is the total cost for research and development activities. View historical data on Grand Brilliance Group Holdings and its competitors. Grand Brilliance Group Holdings's current Research & Development is HK$0.0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Grand Brilliance Group Holdings stock overvalued right now?
Based on GuruFocus' analysis, Grand Brilliance Group Holdings (HKSE:08372) is currently considered Fairly Valued. The stock's GF Value™ is HK$0.12, compared to a current price of HK$0.13 — trading 5.8% above its estimated fair value. The current Research & Development is HK$0.0 Mil. Grand Brilliance Group Holdings' overall GF Score™ is 66/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Research & Development calculated?
Research & Development is calculated from a company's financial statements. For Grand Brilliance Group Holdings (HKSE:08372), the current Research & Development is HK$0.0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Grand Brilliance Group Holdings (HKSE:08372) Overvalued in 2026?

Based on GuruFocus' analysis, Grand Brilliance Group Holdings stock appears to be overvalued. The current stock price of HK$0.13 is trading 5.8% above its estimated GF Value™ of HK$0.12. GuruFocus considers Grand Brilliance Group Holdings to be Fairly Valued.

Key valuation signals for HKSE:08372:

  • Research & Development: HK$0.0 Mil
  • GF Value™: HK$0.12 vs. price of HK$0.13 (5.8% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the HKSE:08372 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Grand Brilliance Group Holdings Business Description

Address 6 Sha Tsui Road, The Octagon, Units 2901-2903 and 2905, 29th Floor, New Territories, Tsuen Wan, Hong Kong, HKG
Grand Brilliance Group Holdings Ltd is an investment holding. The company is engaged in the business of medical device distribution. The company also provides one-stop medical device solutions, including market trend analysis, sourcing of medical devices, after-sale services, technical support, and training services, medical device leasing services, and quality assurance. Geographically, the company derives revenue from Hong Kong. It serves private hospitals, public hospitals, private clinics, non-profit organizations, universities, and individual end-users in Hong Kong.
66GF Score

Get the complete analysis for HKSE:08372

Research & Development is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

HK$0.13
Price
HK$0.12
GF Value